Clinical Trial

A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable schizophrenia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-14.
Trial Details
NCT Number NCT07230652
Lead Sponsor Luye Pharma Group Ltd.
Conditions Schizophrenia, Alzheimer's Disease Psychosis
Enrollment 40 participants
Start Date 2025-08-20
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-11-19